Switchability and Minimal Effect of Food Effect on Pharmacokinetics of Modified Release Tablet Strengths of Omecamtiv Mecarbil, a Cardiac Myosin Activator

Author(s):  
Ashit Trivedi ◽  
Rajneet K. Oberoi ◽  
Mia Mackowski ◽  
Pegah Jafarinasabian ◽  
Hanze Zhang ◽  
...  
2009 ◽  
Vol 9 (13) ◽  
pp. 1504-1517 ◽  
Author(s):  
J. Zarate ◽  
M. Igartua ◽  
R. Hernandez ◽  
J. Pedraz

Author(s):  
John R. Teerlink ◽  
Rafael Diaz ◽  
G. Michael Felker ◽  
John J.V. McMurray ◽  
Marco Metra ◽  
...  

2018 ◽  
Vol 96 (7) ◽  
pp. 676-680
Author(s):  
Péter Nánási ◽  
István Komáromi ◽  
János Almássy

Clinical treatment of heart failure is still not fully solved. A novel class of agents, the myosin motor activators, acts directly on cardiac myosin resulting in an increased force generation and prolongation of contraction. Omecamtiv mecarbil, the lead molecule of this group, is now in human phase 3 displaying promising clinical performance. However, omecamtiv mecarbil is not selective to myosin, because it readily binds to and activates cardiac ryanodine receptors (RyR-2), an effect that may cause complications in case of overdose. In this study, in silico analysis was performed to investigate the docking of omecamtiv mecarbil and other structural analogues to cardiac myosin heavy chain and RyR-2 to select the structure that has a higher selectivity to myosin over RyR-2. In silico docking studies revealed that omecamtiv mecarbil has comparable affinity to myosin and RyR-2: the respective Kd values are 0.60 and 0.87 μmol/L. Another compound, CK-1032100, has much lower affinity to RyR-2 than omecamtiv mecarbil, while it still has a moderate affinity to myosin. It was concluded that further research starting from the chemical structure of CK-1032100 may result a better myosin activator burdened probably less by the RyR-2 binding side effect. It also is possible, however, that the selectivity of omecamtiv mecarbil to myosin over RyR-2 cannot be substantially improved, because similar moieties seem to be responsible for the high affinity to both myosin and RyR-2.


2009 ◽  
Vol 98 (4) ◽  
pp. 1568-1576 ◽  
Author(s):  
J. Davis ◽  
J. Burton ◽  
A.L. Connor ◽  
R. Macrae ◽  
I.R. Wilding

The Lancet ◽  
2011 ◽  
Vol 378 (9792) ◽  
pp. 667-675 ◽  
Author(s):  
John R Teerlink ◽  
Cyril P Clarke ◽  
Khalil G Saikali ◽  
Jacqueline H Lee ◽  
Michael M Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document